POET Technologies: When a Breakthrough Technology Meets a Broken Trust

POET's optical interposer technology faces a critical test as Marvell fallout, class-action lawsuit, and heavy losses overshadow its product roadmap.

The physics of copper wiring is running out of road. As data centers push toward ever-higher computing densities, the energy consumed just shuttling information between chips has become a critical bottleneck. Optical interconnects offer a way out, and POET Technologies has built its entire thesis around that transition. The company's optical interposer platform, which fuses electronics and photonics on a single substrate, is precisely the kind of technology that hyperscalers and chipmakers will need as networks migrate from 800G to 1.6T standards.

But technology alone doesn't make a stock. And right now, POET's shares are caught between a genuinely promising product roadmap and a series of operational setbacks that have shaken investor confidence to its core.

The Marvell Fallout

The most damaging blow came in late April 2026, when Marvell Semiconductor cancelled all outstanding orders with Celestial AI — the subsidiary through which POET had been supplying components. Marvell cited a breach of confidentiality obligations, alleging that POET had shared sensitive details about orders and deliveries without authorization.

That single event has reverberated far beyond the lost revenue. It triggered a securities class-action lawsuit accusing the company of fraud, and it severed what many analysts considered the linchpin of the bull case: POET's relationship with the Marvell/Celestial AI ecosystem. New supply agreements, including a deal with Lumilens, demonstrate that the company is still operating and winning business. But they do little to repair the reputational damage. A major Tier-1 customer publicly withdrew its trust, and that stain is not easily washed away.

The Numbers Behind the Narrative

The financial reality is stark. POET reported a net loss of $81.65 million against just $1.41 million in revenue, all of it from Asia. That gap between cash burn and commercial traction explains why the market remains so deeply divided.

The stock currently trades at €6.76, up 0.75% on the day — a modest bounce that does little to mask the scale of the recent selloff. Over the past 30 days, the shares have lost 27.78%, and from the 52-week high of €18.84 reached in mid-May, they have fallen 64.12%. Yet the stock remains nearly 99% above its 52-week low, a reminder that the current price still embeds far more optimism than existed a year ago.

The price-to-book ratio of 2.9 sits well below the semiconductor sector average of roughly 5.3. Some analysts interpret that as a sign of undervaluation following the rout. But the comparison is misleading for a company generating negligible revenue — a low book multiple says little about operating substance when the denominator is mostly cash and intellectual property.

Dilution: The Silent Drag

To fund its research and development, POET has repeatedly turned to equity issuance. The share count has ballooned over the years, steadily diluting long-term holders. Market reports suggest the company may need to raise approximately $250 million to scale its manufacturing capacity — a capital requirement that would further dilute existing shareholders.

This structural dynamic limits upside potential even if the optical interposer technology eventually gains traction. Scaling semiconductor fabrication is capital-intensive, and the money has to come from somewhere. For current shareholders, that somewhere is usually their own stake.

A Stock That Moves on Sentiment, Not Fundamentals

With an annualized 30-day volatility of over 91%, POET remains one of the most volatile names in the photonics space. The relative strength index sits at 39.3, approaching oversold territory, but a clear catalyst for a trend reversal has yet to emerge.

The company's own revenue guidance for 2026 — between $50 million and $125 million — implies a dramatic ramp from current levels. The Lumilens deal and other production orders now run into the millions of dollars, suggesting progress from prototype to manufacturing. But the gap between where POET is today and where it needs to be to justify its current valuation remains enormous.

The fundamental question is not whether POET's technology works. It almost certainly does. The question is whether the company can scale fast enough to outrun its capital needs and rebuild the trust that the Marvell episode shattered. The next quarterly reports will show whether those million-dollar orders are the beginning of a trajectory toward the 2026 revenue target — or whether the financing gap is widening faster than the top line.